Skip to content

Efficacy evaluation study for EMMA and ALICE test in multi-centers. A joint research with Japanese Institution for Standardizing Assisted Reproductive Technology (JISART)

Efficacy evaluation study for EMMA and ALICE test in multi-centers. A joint research with Japanese Institution for Standardizing Assisted Reproductive Technology (JISART) - EMMA/ALICE efficacy evaluation

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000036917
Enrollment
500
Registered
2019-06-01
Start date
2019-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Chronic Endometritis

Interventions

Endometrial tissue will be obtained from patients by aspiration using a Pipelle catheter (or similar) on 15-25 day of menstrual cycle and will be used for the diagnosis of the microbiome by Next-gener

Sponsors

The Japanese Institution for Standardizing Assisted Reproductive Technology (JISART)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1, Patients undergoing ART treatments in JISART registered institutions, with scheduled embryo implantation 2, Patients who can perform re-examination if necessary

Exclusion criteria

Exclusion criteria: 1, Patients with intrauterine lesions (surgically-adapted uterine submucosal myomas and endometrial polyps, Asherman syndrome, cesarean section scarring syndrome, etc.) 2, Patients with metabolic abnormality (thyroid disease of poor control etc.) and medical complication 3, Couples, or their parents, with abnormal chromosomes, including translocation 4, Patients with fallopian cysts without medical treatments 5, Patients with allergy to antibiotics, or patients who cannot follow antibiotic treatments 6, Patients who have taken prescribed antibiotics at least 3 months before the sample collection. (Cases where the patient has received previous prophylactic antibiotics to ovarian puncture in the stimulation cycle, according to the standard clinical practice of the clinic, may be accepted if the administration of the antibiotic was made at least 1 month before the sample collection). 7, Patients who have taken antibiotics other than those recommended by EMMA/ALICE between sample collection and embryo transfer. 8, Any illness or medical condition that is unstable or can put patient safety at risk and compromise the compliance of the study.

Design outcomes

Primary

MeasureTime frame
Ongoing pregnancy rate. Participant centers should treat the patients following the descriptions specified in EMMA/ALICE reports, antibiotic treatments, probiotic treatments, re-analysis, and embryo transfer after re-analysis. All patients participating in this study should obtain re-analysis if necessary. Data of ongoing pregnancy rates should be collected by participant centers after embryo implantation for analysis.

Secondary

MeasureTime frame
1.One variable per each microorganism identified in endometrial biopsy. 2.Microbiome found in endometrial biopsy (LD/NLD) Presence of bacterial microbiome; Identified bacteria are classified into the following two groups: Group 1 (LD): Lactobacillus dominated microbiome (>90% Lactobacillus spp.), composed of different species of the genus Lactobacillus: L. crispatus, L. gasseri, L. iners, L.jensenii, among others. Group 2 (NLD): non-Lactobacillus dominated microbiome (<90% Lactobacillus spp. with at least 10% of dysbiotic bacteria), formed by species that modify the physiological endometrial conditions, therefore decreasing the prevalence of Lactobacillus Analysis implantation rate, Live Birth rates and Miscarriage rate after embryo implantation.

Countries

Japan

Contacts

Public ContactRie HIrokawa

The Japanese Institution for Standardizing Assisted Reproductive Technology (JISART) Reproductive Health

hirokawa@jisart.jp0661319741

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026